专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100216168A1 METHODS FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE 审中-公开
标题翻译：用于评估文化中的生殖潜力的方法
公开(公告)号：US20100216168A1
公开(公告)日：2010-08-26
申请号：US12530541
申请日：2008-03-24
申请人： Jamie Heinzman , Stacey Brower , Jason Bush , Zhibao Mi
发明人： Jamie Heinzman , Stacey Brower , Jason Bush , Zhibao Mi
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , G01N33/5011 , G01N2800/52
摘要： The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-β1, TGF-β2, TGF-β3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.
摘要翻译：本发明提供一种评价肿瘤血管生成潜力的方法，以及用于个体化预测抗血管生成疗法的功效。本发明的方法包括通过测定选自VEGF / VPF，IL8 / CXCL8，TGF-β1，TGF-β1的一种或多种血管生成相关因子的存在或水平来制备培养中恶性细胞的血管生成特征。 2，TGF-βb，3，bFGF / FGF-2，EGF，PDGF-AA，PDGF-AA / BB，IP-10和Flt-3配体。血管生成特征可以由维持在常氧和/或缺氧环境下的培养物制备。本发明可以与抗肿瘤剂的化学应答测试结合使用，以预测或建议癌症患者的联合疗法。

2. 发明申请

US20080085519A1 Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics 有权
标题翻译：使用表现出持久表型特征的肿瘤细胞的化学敏感性测定
公开(公告)号：US20080085519A1
公开(公告)日：2008-04-10
申请号：US11785984
申请日：2007-04-23
申请人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Rice , Anuja Chattopadhyay
发明人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Rice , Anuja Chattopadhyay
IPC分类号： G01N33/574 , C12N5/06 , C12Q1/02 , C12Q1/68
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.
摘要翻译：本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测个体患者恶性肿瘤的进展。本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测和鉴定细胞和分泌标记物，用于筛选细胞以检测表型和基因型漂移，并用于预测患者肿瘤细胞对至少一种治疗剂的化疗反应。本文所讨论的测定法，方法，工具和系统也表示改进和统一的系统，用于监测和筛选多种药剂，用于特定患者的功效和长期效果。

3. 发明授权

US08236489B2 Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics 有权
标题翻译：使用表现出持久表型特征的肿瘤细胞的化学敏感性测定
公开(公告)号：US08236489B2
公开(公告)日：2012-08-07
申请号：US12622022
申请日：2009-11-19
申请人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
发明人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
IPC分类号： G01N33/574 , G01N33/577 , C12N5/02 , C12N5/06 , C12N5/09 , C12Q1/00
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.
摘要翻译：本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测个体患者恶性肿瘤的进展。本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测和鉴定细胞和分泌标记物，用于筛选细胞以检测表型和基因型漂移，并用于预测患者肿瘤细胞对至少一种治疗剂的化疗反应。本文所讨论的测定法，方法，工具和系统也表示改进和统一的系统，用于监测和筛选多种药剂，用于特定患者的功效和长期效果。

4. 发明申请

US20120329086A1 CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS 审中-公开
标题翻译：使用肿瘤细胞的化学敏感性测定显示出不同的PHENOTYPIC特性
公开(公告)号：US20120329086A1
公开(公告)日：2012-12-27
申请号：US13542000
申请日：2012-07-05
申请人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
发明人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
IPC分类号： C12Q1/18
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.
摘要翻译：本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测个体患者恶性肿瘤的进展。本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测和鉴定细胞和分泌标记物，用于筛选细胞以检测表型和基因型漂移，并用于预测患者肿瘤细胞对至少一种治疗剂的化疗反应。本文所讨论的测定法，方法，工具和系统也表示改进和统一的系统，用于监测和筛选多种药剂，以确定特定患者的功效和长期效果。

5. 发明申请

US20100311084A1 METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS 审中-公开
标题翻译：方法预防患者对EGFR抑制剂的反应
公开(公告)号：US20100311084A1
公开(公告)日：2010-12-09
申请号：US12795286
申请日：2010-06-07
申请人： Stacey Brower , Shara D. Rice , Theresa R. Cassino , Lahari Sakhamuri , Heather M. Buechel , Lauren M. Hancher
发明人： Stacey Brower , Shara D. Rice , Theresa R. Cassino , Lahari Sakhamuri , Heather M. Buechel , Lauren M. Hancher
IPC分类号： G01N33/574
CPC分类号： G01N33/5091 , G01N33/574 , G01N2333/485 , G01N2800/52
摘要： The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to a monoclonal EGFR antibody, such as cetuximab. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with a monoclonal EGFR antibody that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the monoclonal EGFR antibody during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen).
摘要翻译：本发明提供了用于个体化癌症治疗化学疗法的方法，特别是用于评估患者在用这些药物治疗之前对一种或多种表皮生长因子受体（EGFR）抑制剂的反应性。特别地，本发明提供了用于预测患者对单克隆EGFR抗体如西妥昔单抗的应答的体外化学应答测定。该方法通常包括从患者标本（例如活检标本）培养恶性细胞，使培养的细胞与作为患者候选治疗的单克隆EGFR抗体接触，并评价培养细胞对药物的应答。在某些实施方案中，从通过切割肿瘤组织制备的外植体培养恶性细胞的单层，并将单层细胞悬浮并铺板以进行化学敏感性测试。通过本发明的方法确定的对药物的体外应答与在化疗期间接受单克隆EGFR抗体（例如，与其他标准化或个体化化学治疗方案组合）时患者体内应答相关。

6. 发明申请

US20100143948A1 CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS 有权
标题翻译：使用肿瘤细胞的化学敏感性测定显示出不同的PHENOTYPIC特性
公开(公告)号：US20100143948A1
公开(公告)日：2010-06-10
申请号：US12622022
申请日：2009-11-19
申请人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
发明人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
IPC分类号： G01N33/574
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.
摘要翻译：本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测个体患者恶性肿瘤的进展。本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测和鉴定细胞和分泌标记物，用于筛选细胞以检测表型和基因型漂移，并用于预测患者肿瘤细胞对至少一种治疗剂的化疗反应。本文所讨论的测定法，方法，工具和系统也表示改进和统一的系统，用于监测和筛选多种药剂，用于特定患者的功效和长期效果。

7. 发明授权

US07642048B2 Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics 有权
标题翻译：使用表现出持久表型特征的肿瘤细胞的化学敏感性测定
公开(公告)号：US07642048B2
公开(公告)日：2010-01-05
申请号：US11785984
申请日：2007-04-23
申请人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
发明人： Michael Gabrin , Stacey Brower , Sean McDonald , Holly Gallion , Payal Nanavati , Shara Dawn Rice , Anuja Chattopadhyay
IPC分类号： C12N5/02 , C12N5/06 , C12Q1/00 , C12N5/08
CPC分类号： G01N33/57407 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient.
摘要翻译：本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测个体患者恶性肿瘤的进展。本文讨论的测定，方法，工具和系统表示改进和统一的系统，用于监测和鉴定细胞和分泌标记物，用于筛选细胞以检测表型和基因型漂移，并用于预测患者肿瘤细胞对至少一种治疗剂的化疗反应。本文所讨论的测定法，方法，工具和系统也表示改进和统一的系统，用于监测和筛选多种药剂，用于特定患者的功效和长期效果。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式